Toremifene

Toremifene

Clinical data
Trade names	Fareston
AHFS/Drugs.com	Monograph
MedlinePlus	a608003
ATC code	L02BA02 (WHO)
Pharmacokinetic data
Protein binding	More than 99.5%
Biological half-life	5 days
Identifiers
IUPAC name 2-{4-[(1Z)-4-chloro-1,2-diphenyl-but-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
CAS Number	89778-26-7 Y
PubChem CID	3005573
IUPHAR/BPS	4325
DrugBank	DB00539 Y
ChemSpider	2275722 Y
UNII	7NFE54O27T
KEGG	D08620 Y
ChEBI	CHEBI:9635 Y
ChEMBL	CHEMBL1655 Y
PDB ligand	T0R (PDBe, RCSB PDB)
ECHA InfoCard	100.125.139
Chemical and physical data
Formula	C26H28ClNO
Molar mass	405.959 g/mol
3D model (Jmol)	Interactive image
SMILES ClCCC(/c1ccccc1)=C(/c2ccc(OCCN(C)C)cc2)c3ccccc3
InChI InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25- Y Key:XFCLJVABOIYOMF-QPLCGJKRSA-N Y

Toremifene citrate (/ˈtoʊrᵻmᵻfin/) is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.

In 2007 the pharmaceutical company GTx, Inc was conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy (ADT) (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008

An NDA for the first application (relief of prostate cancer ADT side effects) was submitted in Feb 2009, and in Oct 2009 the FDA said they would need more clinical data, e.g. another phase III trial.